All In Biotech

Drug Trial Radar · NCT04445064

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

Activity and Safety of Peptide-based Immunotherapy in an Umbrella Window-of-opportunity Phase II Study in Patients With Squamous Cell Carcinoma of the Head and Neck.

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

17

Actual

Start

Aug 14, 2020

Primary completion

Jun 8, 2024

Study completion Mar 20, 2025

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

Conditions

  • Oropharynx Squamous Cell Carcinoma
  • Larynx Squamous Cell Carcinoma
  • Hypopharynx Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma

Interventions

  • IO102Biological

    100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)

  • IO103Biological

    100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with a T-cell peptide-specific response to the vaccine as assessed by an interferon(INF)-γ ELISpot assay.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.